HRP20110374T1 - Upotreba anti-cd151 antitijela kod liječenja primarnog raka - Google Patents
Upotreba anti-cd151 antitijela kod liječenja primarnog raka Download PDFInfo
- Publication number
- HRP20110374T1 HRP20110374T1 HR20110374T HRP20110374T HRP20110374T1 HR P20110374 T1 HRP20110374 T1 HR P20110374T1 HR 20110374 T HR20110374 T HR 20110374T HR P20110374 T HRP20110374 T HR P20110374T HR P20110374 T1 HRP20110374 T1 HR P20110374T1
- Authority
- HR
- Croatia
- Prior art keywords
- cdr
- antibody
- seq
- use according
- sequences
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract 7
- 206010027476 Metastases Diseases 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000000824 cytostatic agent Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 230000004614 tumor growth Effects 0.000 claims abstract 2
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0609135A FR2907341B1 (fr) | 2006-10-18 | 2006-10-18 | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
| PCT/FR2007/001688 WO2008049990A2 (fr) | 2006-10-18 | 2007-10-15 | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110374T1 true HRP20110374T1 (hr) | 2011-06-30 |
Family
ID=37866318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110374T HRP20110374T1 (hr) | 2006-10-18 | 2011-05-19 | Upotreba anti-cd151 antitijela kod liječenja primarnog raka |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8178096B2 (es) |
| EP (1) | EP2079482B1 (es) |
| JP (2) | JP5757646B2 (es) |
| KR (1) | KR101521863B1 (es) |
| CN (1) | CN101528256B (es) |
| AT (1) | ATE499387T1 (es) |
| AU (1) | AU2007310763B2 (es) |
| BR (1) | BRPI0717455A2 (es) |
| CA (1) | CA2665912C (es) |
| DE (1) | DE602007012743D1 (es) |
| DK (1) | DK2079482T3 (es) |
| ES (1) | ES2361696T3 (es) |
| FR (1) | FR2907341B1 (es) |
| HK (1) | HK1132904A1 (es) |
| HR (1) | HRP20110374T1 (es) |
| IL (1) | IL198043A (es) |
| MA (1) | MA30777B1 (es) |
| MX (1) | MX2009003039A (es) |
| NO (1) | NO20091919L (es) |
| NZ (1) | NZ575781A (es) |
| PL (1) | PL2079482T3 (es) |
| PT (1) | PT2079482E (es) |
| RS (1) | RS51729B (es) |
| RU (1) | RU2464041C2 (es) |
| SI (1) | SI2079482T1 (es) |
| TN (1) | TN2009000144A1 (es) |
| UA (1) | UA99601C2 (es) |
| WO (1) | WO2008049990A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| FR2907341B1 (fr) * | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
| FR2929946B1 (fr) * | 2008-04-11 | 2010-05-28 | Pf Medicament | Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer |
| EP2308897A1 (en) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
| EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
| WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
| CN102605057A (zh) * | 2012-02-28 | 2012-07-25 | 芮屈生物技术（上海）有限公司 | 癌症病变前期CD151的mRNA水平原位杂交检测试剂盒及检测方法和应用 |
| US9982057B2 (en) | 2014-11-17 | 2018-05-29 | Pelican Therapeutics, Inc. | Human TNFRSF25 antibody |
| CN109219620B (zh) | 2016-06-09 | 2023-01-31 | 派立卡恩治疗公司 | 抗-tnfrsf25抗体 |
| CN108690136B (zh) * | 2017-04-05 | 2022-09-20 | 凯惠科技发展(上海)有限公司 | 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| WO1999066027A1 (en) * | 1998-06-15 | 1999-12-23 | The Research Foundation Of State University Of New York | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
| JP2003189851A (ja) * | 2001-12-28 | 2003-07-08 | Japan Science & Technology Corp | 抗ヒトｃｄ１５１モノクローナル抗体産生ハイブリドーマ |
| JP2003321494A (ja) | 2002-02-26 | 2003-11-11 | Daiichi Fine Chemical Co Ltd | プロｍｍｐ−７の活性化調節方法 |
| EP2041175A4 (en) * | 2006-06-23 | 2011-03-16 | Augmenta Biolog Llc | TARGETED IMMUNOJUGATE |
| FR2907341B1 (fr) * | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
| FR2929946B1 (fr) * | 2008-04-11 | 2010-05-28 | Pf Medicament | Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer |
-
2006
- 2006-10-18 FR FR0609135A patent/FR2907341B1/fr not_active Expired - Fee Related
-
2007
- 2007-10-15 DE DE602007012743T patent/DE602007012743D1/de active Active
- 2007-10-15 CN CN2007800389060A patent/CN101528256B/zh not_active Expired - Fee Related
- 2007-10-15 UA UAA200904808A patent/UA99601C2/ru unknown
- 2007-10-15 US US12/311,682 patent/US8178096B2/en not_active Expired - Fee Related
- 2007-10-15 WO PCT/FR2007/001688 patent/WO2008049990A2/fr active Application Filing
- 2007-10-15 KR KR1020097010125A patent/KR101521863B1/ko active IP Right Grant
- 2007-10-15 SI SI200730592T patent/SI2079482T1/sl unknown
- 2007-10-15 BR BRPI0717455-1A2A patent/BRPI0717455A2/pt active Search and Examination
- 2007-10-15 DK DK07858450.5T patent/DK2079482T3/da active
- 2007-10-15 AT AT07858450T patent/ATE499387T1/de active
- 2007-10-15 RS RS20110202A patent/RS51729B/en unknown
- 2007-10-15 RU RU2009118440/15A patent/RU2464041C2/ru not_active IP Right Cessation
- 2007-10-15 JP JP2009532841A patent/JP5757646B2/ja not_active Expired - Fee Related
- 2007-10-15 PT PT07858450T patent/PT2079482E/pt unknown
- 2007-10-15 MX MX2009003039A patent/MX2009003039A/es active IP Right Grant
- 2007-10-15 EP EP07858450A patent/EP2079482B1/fr active Active
- 2007-10-15 NZ NZ575781A patent/NZ575781A/en not_active IP Right Cessation
- 2007-10-15 CA CA2665912A patent/CA2665912C/fr not_active Expired - Fee Related
- 2007-10-15 PL PL07858450T patent/PL2079482T3/pl unknown
- 2007-10-15 ES ES07858450T patent/ES2361696T3/es active Active
- 2007-10-15 AU AU2007310763A patent/AU2007310763B2/en not_active Ceased
-
2009
- 2009-04-03 MA MA31758A patent/MA30777B1/fr unknown
- 2009-04-06 IL IL198043A patent/IL198043A/en active IP Right Grant
- 2009-04-17 TN TNP2009000144A patent/TN2009000144A1/fr unknown
- 2009-05-18 NO NO20091919A patent/NO20091919L/no not_active Application Discontinuation
- 2009-11-10 HK HK09110445.1A patent/HK1132904A1/xx not_active IP Right Cessation
-
2011
- 2011-05-19 HR HR20110374T patent/HRP20110374T1/hr unknown
-
2012
- 2012-04-16 US US13/447,626 patent/US20120219569A1/en not_active Abandoned
-
2013
- 2013-07-09 JP JP2013143422A patent/JP5723420B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110374T1 (hr) | Upotreba anti-cd151 antitijela kod liječenja primarnog raka | |
| JP2018070648A5 (es) | ||
| US10519236B2 (en) | Antibodies specific to delta 1 chain of T cell receptor | |
| HRP20191169T1 (hr) | Konjugati antidll3-protutijelo-pbd i njihove uporabe | |
| JP2019110906A5 (es) | ||
| HRP20180104T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 | |
| DK2220121T3 (en) | AXL antibodies | |
| JP2013519375A5 (es) | ||
| JP2009518039A5 (es) | ||
| JP2020502271A5 (es) | ||
| JP2011046732A5 (es) | ||
| RU2012154339A (ru) | НОВОЕ АНТИТЕЛО ПРОТИВ c-Met | |
| JP2015509948A5 (es) | ||
| JP2022101693A5 (es) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2013510868A5 (es) | ||
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2016538318A5 (es) | ||
| JP2017511376A5 (es) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
| FI3218005T3 (fi) | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä | |
| KR20160044042A (ko) | 부위-특이적 항체 접합 방법 및 조성물 | |
| JP2016537383A5 (es) | ||
| RS54452B1 (en) | INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER |